Noetik, an AI-native biotechnology company specializing in precision cancer therapies, has appointed Dr. Emily Corse as Executive Vice President of Therapeutics. Dr. Corse will oversee Noetik’s pipeline, guiding therapeutics from discovery through translational development and early clinical execution.
Dr. Corse brings extensive expertise in cancer immunotherapy, having trained under Nobel Laureate Dr. Jim Allison and later establishing her research group at MD Anderson Cancer Center. Her career has focused on translating immune biology into impactful therapies. She has held leadership roles at Roche Switzerland and Boehringer-Ingelheim, advancing programs in target validation, drug discovery, and Phase 1 clinical testing. Most recently, she served as Executive Vice President of Biology and Translation at Larkspur Biosciences.
Ron Alfa, M.D., Ph.D., CEO and Co-Founder of Noetik, said “Emily is an exceptional leader with deep expertise in cancer immunotherapy. Her proven track record, coupled with her dynamic energy, clarity of vision, and relentless drive to accelerate therapies to patients, will be instrumental as Noetik moves to translate insights from frontier models of virtual cell biology into an innovative therapeutics portfolio.”
“I’m thrilled to join Noetik at this pivotal stage,” said Dr. Corse. “The scientific foundation and platform capabilities here are the future of drug development, and the team’s drive to move quickly and thoughtfully is palpable. I look forward to helping advance a pipeline that leverages deep biology, innovative data science, and a shared urgency to make a difference for patients.” she added
About Noetik
Noetik is an AI-native biotechnology company. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision therapies. The company is based in San Francisco, CA.
